Table 1 Comparison of GOG phases 3 randomized clinical trials for women with recurrent or advanced cervical cancer. GOG Protocols 169, 179, 204, 240 and JGOG 0505

Modalities

Cis ± Pac

Cis ± Topo

Cis-Pac

Ctx vs Ctx + bevacizumab

CDDP-Pac vs CB-Pac

vs Cis- Topo

vs Cis- GC

vs Cis-VR

Stage

IVB, recurrent, or persistent SCC

IVB, recurrent, or persistent SCC

IVB, recurrent, or persistent SCC, ACA, or ASC

IVB, recurrent, or persistent SCC, ACA, or ASC

IVB, recurrent, or persistent SCC, ACA, or ASC

N

264

293

513

452

253

PS

0–2

0–2

0–1

0–1

0–2

ORR

19 vs 36 %

13 vs 27 %

29.1 vs 23.4 vs 22.3 vs 25.9 %

36 vs 48 %

-

PFS

2.8 vs 4.8 mo

2.9 vs 4.6 mo

5.8 vs 4.6 vs 4.7 vs 3.9 mo

5.9 vs 8.2 mo

6.9 vs 6.21

P value

<001

NS

.06 vs .04 vs .19

.002

.004

OS

8.8 vs 9.7 mo

6.5 vs 9.4 mo

12.8 vs 10.2 vs 10.3 vs 9.9 mo

13.3 vs 17 mo

18.3 vs 17.5 mo

P value

NS

.021

.71 vs .90 vs .89

.004

.032